Navigation Links
Notre Dame researchers demonstrate antibiotic sensing event central to MSRA antibiotic resistance
Date:9/15/2011

A new paper by a team of University of Notre Dame researchers that included Shahriar Mobashery, Jeffrey Peng, Brian Baker and their researchers Oleg Borbulevych, Malika Kumararasiri, Brian Wilson, Leticia Llarrull, Mijoon Lee, Dusan Hesek and Qicun Shi describes a unique process that is central to induction of antibiotic resistance in the problematic bacterium methicillin-resistant Staphylococcus aureus (MSRA).

MRSA first emerged in the United Kingdom in 1961and spread rapidly across the globe. Modern strains of MRSA are broadly resistant to antibiotics of various classes, but resistance to B-lactam antibiotics, which include penicillins, cephalosporins, and carpapenems, is an acute problem because it impacts virtually all commercially available members of the class.

Earlier research by Mobashery, who holds the Navari Family Chair of Life Sciences at Notre Dame, found that an antibiotic sensor/signal transducer protein called "BlaR1" is a key player in MRSA's resistance to β-lactam antibiotics. Specifically, he had detected by spectroscopy a unique recognition process by the BlaR1 protein of the antibiotic that the organism might encounter. This recognition event, termed "Lysine N-Decarboxylation Switch," involved formation of an N-carboxylated lysine within the antibiotic-binding domain of BlaR1, which experiences decarboxylation on binding to the antibiotic. This decarboxylation gives the antibiotic complex longevity, which benefits MRSA in the face of the antibiotic challenge. Although this antibiotic-recognition event was described by Mobashery's research group a few years earlier, the process was not visualized in atomic resolution, despite attempts by several other research groups.

The three collaborating groups of Notre Dame researchers approached the problem differently. The Peng group studies the process by three- and two-dimensional NMR spectroscopy in Notre Dame's Lizzardo Magnetic Resonance Research Center, the Baker group grew new crystals of the protein for x-ray diffraction and the Mobashery group applied computational methods to understand the process.

The efforts paid off, as Peng demonstrated the presence of N-carboxylated lysine in the protein and showed that it undergoes N-decarboxylation on binding to the antibiotic in solution. Baker visualized both the N-carboxylated lysine in the x-ray crystal structure of the uncomplexed form and showed that when the antibiotic complexed with the protein, the N-decarboxylation switch resulted in a stable complex critical to the manifestation of resistance.

The lysine N-decarboxylation switch triggers MRSA's antibiotic sensor domain to adopt the active state that leads to all the subsequent biochemical processes that enable resistance, an event that was investigated by computational analyses in the Mobashery lab in the present study.

The importance of this lysine N-decarboxylation switch for MRSA rests in the fact that the organism does not mobilize its resources until and unless it is exposed to the antibiotic. As such, in an economy of existence, the MRSA conserves its resources until BlaR1 informs it that it has come in contact with a B-lactam antibiotic.

The research paper describing the team's findings appears in the Journal of Biological Chemistry.


'/>"/>

Contact: Shahriar Mobashery
mobashsery@nd.edu
574-631-2932
University of Notre Dame
Source:Eurekalert

Related biology news :

1. Notre Dame research reveals brain network connections
2. Breakthrough in Niemann-Pick Type C research reported by Notre Dame and Cornell scientists
3. Notre Dame research offers important clues about grasshopper population explosions
4. Notre Dame biologists call for regulation of rare plant sales
5. Notre Dame researcher helps discover walking properties of bacteria
6. Notre Dame and Wyoming scientists genetically engineer silkworms to produce artificial spider silk
7. Twins are intriguing research subjects for Notre Dame biometircs researchers
8. Notre Dame study focuses on protein dynamics
9. Notre Dame researchers describe new tool for evaluating managed relocations
10. Researchers uncover a potential new benefit of pure maple syrup on liver health
11. EPA grants help Wayne State researchers stave off Great Lakes environmental invaders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/14/2017)... N.C. , Feb. 14, 2017  Wake Forest ... M.D., as its new chief executive officer (CEO). Freischlag ... CEO John D. McConnell , M.D., who last ... position at the Medical Center, after leading it since ... the full scope of Wake Forest Baptist,s academic health ...
(Date:2/8/2017)... Feb. 8, 2017 About Voice Recognition Biometrics ... match it against a stored voiceprint template. Acoustic ... cadence, and tone are compared to distinguish between ... installation, as most PCs already have a microphone ... Voice recognition biometrics are most likely to be ...
(Date:2/7/2017)... MINNETONKA, Minn. , Feb. 7, 2017   ... that supports the entire spectrum of clinical research, is ... iMedNet , its innovative, highly flexible and ... iMedNet customers. iMedNet is a ... only provides Electronic Data Capture (EDC), but also delivers ...
Breaking Biology News(10 mins):
(Date:2/16/2017)... 2017  Windtree Therapeutics, Inc. (Nasdaq: ... aerosolized KL4 surfactant therapies for respiratory diseases, announced ... showed that aerosolized KL4 surfactant reduced lung inflammation ... animal model. The Company believes that these preclinical ... that supports the role of KL4 surfactant as ...
(Date:2/16/2017)... NEW YORK , Feb. 16, 2017 /PRNewswire/ ... their $7M Series B financing, adding an additional $3M ... led by Mesa Verde Venture Partners and other strategic ... be directed towards further accelerating commercial adoption of their ... profiling test and expanding the Paradigm cancer registry. ...
(Date:2/15/2017)... ... February 15, 2017 , ... Executive search firm, ... Officer with GenePeeks. Matt is a veteran life sciences and molecular diagnostics ... company focused on identifying inherited disease risk in future generations. In his new ...
(Date:2/15/2017)... , 15. Februar 2017  Trianni, Inc. („TRIANNI") ... Inc. (Janssen) eine Lizenzvereinbarung über die Verwendung der ... führenden Plattform für die Entdeckung monoklonaler Antikörper. ... neuartiges chimäres Gensegmentdesign aus, das Janssen den ... Antikörpern bietet und das für die schelle Isolierung ...
Breaking Biology Technology: